HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues
Version of Record online: 21 JAN 2009
© 2009 John Wiley & Sons A/S
Special Issue: International Conference of the Management of Patients with Viral Hepatitis, Paris, 19-20 January 2009
Volume 29, Issue Supplement s1, pages 130–132, January 2009
How to Cite
Lampertico, P. and Colombo, M. (2009), HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues. Liver International, 29: 130–132. doi: 10.1111/j.1478-3231.2008.01931.x
- Issue online: 21 JAN 2009
- Version of Record online: 21 JAN 2009
- Received 8 July 2008Accepted 10 November 2008
- 4Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg negative chronic hepatitis B. Hepatology 2006; 44: 231A., , , et al.
- 5Two-year results from the Globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 2006; 44: 222A., , , et al.
- 6Telbivudine Globe trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006; 44: 230A., , , et al.
- 7Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (The Globe Study). Hepatology 2007; 46: 681A., , , et al.
- 11Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102). J Hepatol 2008; 48: S26: #57., , , et al.
- 17Six years of on demand LAM±ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis. J Hepatol 2007; 46: S189., ,